ハンチンチン治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Huntingtin - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0478
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:77
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥367,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥735,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,102,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Huntingtin – Pipeline Review, H2 2019
Summary

Huntingtin (Huntington Disease Protein or HTT) pipeline Target constitutes close to 19 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The latest report Huntingtin – Pipeline Review, H2 2019, outlays comprehensive information on the Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Huntingtin (Huntington Disease Protein or HTT) – Huntingtin protein is an encoded by the huntingtin gene, also called the HTT or HD (Huntington disease) gene. Huntingtin up regulates the expression of brain derived neurotrophic factor (BDNF) at the transcription level. Huntingtin is primarily associated with vesicles and microtubules.

These indicate an important role in cytoskeletal anchoring or transport of mitochondria. The Htt protein is involved in vesicle trafficking as it interacts with HIP1 to mediate endocytosis. Huntingtin also plays an important role in the establishment in epithelial polarity through its interaction with RAB11A. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 10 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Genetic Disorders which include indications Huntington Disease, Alzheimer’s Disease, Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) and Spinocerebellar Ataxia (SCA).

Furthermore, this report also reviews key players involved in Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Huntingtin (Huntington Disease Protein or HTT)
- The report reviews Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics and enlists all their major and minor projects
- The report assesses Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Huntingtin (Huntington Disease Protein or HTT)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Huntingtin (Huntington Disease Protein or HTT) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Huntingtin (Huntington Disease Protein or HTT) – Overview
Huntingtin (Huntington Disease Protein or HTT) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Huntingtin (Huntington Disease Protein or HTT) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Huntingtin (Huntington Disease Protein or HTT) – Companies Involved in Therapeutics Development
AFFiRiS AG
Dystrogen Therapeutics SA
Exicure Inc
F. Hoffmann-La Roche Ltd
Neurimmune Holding AG
Ophidion Inc
PTC Therapeutics Inc
reMYND NV
Takeda Pharmaceutical Co Ltd
UniQure NV
Voyager Therapeutics Inc
Vybion Inc
Wave Life Sciences Ltd
Huntingtin (Huntington Disease Protein or HTT) – Drug Profiles
AMT-130 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotides to Inhibit HTT for Huntington’s Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotides to Inhibit Huntingtin Protein for Huntington’s Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DYST-201 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Inhibit HTT for Huntington’s disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Inhibit Huntingtin for Huntington Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Inhibit Huntingtin Protein for Huntington’s Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INT-41 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit HTT for Huntington’s Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NI-302 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotide to Inhibit HTT for Huntington Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-301905 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-6042 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Huntingtin Protein for Huntington’s Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Huntingtin Protein for Huntington’s Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Huntingtin for Huntington’s Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VYHTT-01 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WVE-120101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WVE-120102 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Huntingtin (Huntington Disease Protein or HTT) – Dormant Products
Huntingtin (Huntington Disease Protein or HTT) – Product Development Milestones
Featured News & Press Releases
Sep 27, 2019: uniQure to present update on of AMT-130 at European Huntington Association 2019 Conference
Jul 01, 2019: Sangamo Therapeutics announces Nature Medicine publication detailing the activity of disease allele-selective zinc finger proteins in preclinical models of huntington’s disease
May 22, 2019: uniQure strengthens intellectual property portfolio with granted patent claims covering AMT-130 for huntington’s disease
May 07, 2019: uniQure announces featured presentations of new data on AMT-130 at the 2019 American Academy of Neurology Annual Meeting
May 06, 2019: Huntington drug successfully lowers levels of disease-causing protein
Apr 29, 2019: Genentech to present on its Huntington’s Disease drug candidate RG-6042 at the 2019 AAN Annual Meeting Showcase Breadth and Promise of Neuroscience Portfolio
Apr 15, 2019: uniQure to present data on Gene Therapy for Huntington’s Disease at ASGCT 2019
Apr 10, 2019: Wave Life Sciences provides timing update on PRECISION-HD clinical programs
Apr 10, 2019: Wave Life Sciences provides timing update on WVE-120102 Clinical Program
Apr 10, 2019: Wave Life Sciences provides timing update on WVE-120101 clinical Program
Apr 08, 2019: uniQure receives FDA Fast Track Designation for AMT-130 gene therapy for the treatment of Huntington’s Disease
Apr 05, 2019: Dystrogen Therapeutics announces that gene therapy successfully cuts off production of neuron-destroying protein in Huntington’s Disease
Feb 27, 2019: uniQure presents new preclinical data on AMT-130 at the CHDI’s 14th Annual Huntington’s Disease Therapeutics Conference
Jan 28, 2019: First patient enrolled in pivotal study of RG6042 (IONIS-HTT Rx) for people with Huntington’s disease
Jan 22, 2019: uniQure announces FDA clearance of investigational New Drug Application for AMT-130 in Huntington’s Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AFFiRiS AG, H2 2019
Pipeline by Dystrogen Therapeutics SA, H2 2019
Pipeline by Exicure Inc, H2 2019
Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Pipeline by Neurimmune Holding AG, H2 2019
Pipeline by Ophidion Inc, H2 2019
Pipeline by PTC Therapeutics Inc, H2 2019
Pipeline by reMYND NV, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Pipeline by UniQure NV, H2 2019
Pipeline by Voyager Therapeutics Inc, H2 2019
Pipeline by Vybion Inc, H2 2019
Pipeline by Wave Life Sciences Ltd, H2 2019
Dormant Projects, H2 2019

【掲載企業】

AFFiRiS AG
Dystrogen Therapeutics SA
Exicure Inc
F. Hoffmann-La Roche Ltd
Neurimmune Holding AG
Ophidion Inc
PTC Therapeutics Inc
reMYND NV
Takeda Pharmaceutical Co Ltd
UniQure NV
Voyager Therapeutics Inc
Vybion Inc
Wave Life Sciences Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ハンチンチン治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆